Cardiac regulation by phosphoinositide 3-kinases and PTEN.

The diverse effects mediated by PI3K/PTEN (phosphoinositide 3-kinase/phosphatase and tensin homologue deleted on chromosome 10) signalling in the heart clearly support an important biological and pathophysiological role for this signalling cascade. PI3Ks are a family of evolutionarily conserved lipid kinases that mediate many cellular responses to physiological and pathophysiological stimuli. Class I PI3K can be activated by either receptor tyrosine kinase/cytokine receptor activation (class IA) or G-protein-coupled receptors (class IB), leading to the generation of phosphatidyl inositol (3,4,5)P3 and recruitment and activation of Akt/protein kinase B, 3'-phosphoinositide-dependent kinase-1 (PDK1), or monomeric G-proteins, and phosphorylation of a wide range of downstream targets including glycogen synthase kinase 3beta (GSK3beta), mTOR (mammalian target of rapamycin), p70S6 kinase, endothelial nitric oxide synthase, and several anti-apoptotic effectors. Class IA (PI3Kalpha, beta, and delta) and class IB (PI3Kgamma) PI3Ks mediate distinct phenotypes in the heart under negative control by the 3'-lipid phosphatase PTEN, which dephosphorylates PtdIns(3,4,5)P3 to generate PtdIns(4,5)P2. PI3Kalpha, PI3Kgamma, and PTEN are expressed in cardiomyocytes, fibroblasts, endothelial cells, and vascular smooth muscle cells, where they modulate cell survival, hypertrophy, contractility, metabolism, and mechanotransduction. The PI3K/PTEN signalling pathways are involved in a wide variety of diseases including myocardial hypertrophy and contractility, heart failure, and preconditioning. In this review, we discuss the signalling pathways mediated by PI3K class I isoforms and PTEN and their roles in cardiac structure and function.

[1]  G S Taylor,et al.  PTEN and myotubularin: novel phosphoinositide phosphatases. , 2001, Annual review of biochemistry.

[2]  J. Blenis,et al.  Deletion of Ribosomal S6 Kinases Does Not Attenuate Pathological, Physiological, or Insulin-Like Growth Factor 1 Receptor-Phosphoinositide 3-Kinase-Induced Cardiac Hypertrophy , 2004, Molecular and Cellular Biology.

[3]  M. Birnbaum,et al.  Akt1/PKBα Is Required for Normal Growth but Dispensable for Maintenance of Glucose Homeostasis in Mice* , 2001, The Journal of Biological Chemistry.

[4]  J. Penninger,et al.  Phosphatidylinositol 3-Kinase &ggr; Is a Critical Mediator of Myocardial Ischemic and Adenosine-Mediated Preconditioning , 2008, Circulation research.

[5]  Yiling Lu,et al.  Src Family Protein-tyrosine Kinases Alter the Function of PTEN to Regulate Phosphatidylinositol 3-Kinase/AKT Cascades* , 2003, Journal of Biological Chemistry.

[6]  Woojin Jeong,et al.  Reversible Inactivation of the Tumor Suppressor PTEN by H2O2 * , 2002, The Journal of Biological Chemistry.

[7]  Anthony J. Muslin,et al.  Akt1 Is Required for Physiological Cardiac Growth , 2006, Circulation.

[8]  A. Kessler,et al.  Diversification of cardiac insulin signaling involves the p85α/β subunits of phosphatidylinositol 3-kinase , 2001 .

[9]  E. Murphy,et al.  Preconditioning: is the Akt-ion in the PI3K pathway? , 2003, Journal of molecular and cellular cardiology.

[10]  R. B. Campbell,et al.  Allosteric Activation of PTEN Phosphatase by Phosphatidylinositol 4,5-Bisphosphate* , 2003, Journal of Biological Chemistry.

[11]  Kyoung-Han Kim,et al.  Erythropoietin Protects against Doxorubicin-Induced Cardiomyopathy via a Phosphatidylinositol 3-Kinase-Dependent Pathway , 2008, Journal of Pharmacology and Experimental Therapeutics.

[12]  M. Crow,et al.  Phosphatidylinositol 3-Kinase Functionally Compartmentalizes the Concurrent Gs Signaling During &bgr;2-Adrenergic Stimulation , 2002 .

[13]  C. Kontos,et al.  PTEN Modulates Vascular Endothelial Growth Factor-Mediated Signaling and Angiogenic Effects* , 2002, The Journal of Biological Chemistry.

[14]  L. Silengo,et al.  PI3Kγ Modulates the Cardiac Response to Chronic Pressure Overload by Distinct Kinase-Dependent and -Independent Effects , 2004, Cell.

[15]  Jun Ren,et al.  Impaired cardiac function and IGF-I response in myocytes from calmodulin-diabetic mice: role of Akt and RhoA. , 2003, American journal of physiology. Endocrinology and metabolism.

[16]  T. Pedrazzini,et al.  Ischemic postconditioning protects remodeled myocardium via the PI3K-PKB/Akt reperfusion injury salvage kinase pathway. , 2006, Cardiovascular research.

[17]  Thomas Eschenhagen,et al.  Thyroid Hormone Regulates Developmental Titin Isoform Transitions via the Phosphatidylinositol-3-Kinase/ AKT Pathway , 2008, Circulation research.

[18]  J. Schlessinger,et al.  Cell Signaling by Receptor Tyrosine Kinases , 2000, Cell.

[19]  M. Birnbaum,et al.  A conserved role for phosphatidylinositol 3-kinase but not Akt signaling in mitochondrial adaptations that accompany physiological cardiac hypertrophy. , 2007, Cell metabolism.

[20]  I. Shiojima,et al.  Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. , 2005, The Journal of clinical investigation.

[21]  M. N. Poy,et al.  Phosphoinositide 3-Kinase Mediates Enhanced Spontaneous and Agonist-Induced Contraction in Aorta of Deoxycorticosterone Acetate-Salt Hypertensive Rats , 2002, Circulation research.

[22]  B. Nürnberg,et al.  Phosphoinositide 3-Kinase Isoforms Selectively Couple Receptors to Vascular L-Type Ca2+ Channels , 2001 .

[23]  G. Thomas,et al.  Ribosomal S6 kinase signaling and the control of translation. , 1999, Experimental cell research.

[24]  Dianqing Wu,et al.  Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure. , 2003, The Journal of clinical investigation.

[25]  A. Clerk,et al.  Regulation of protein kinase B and 4E-BP1 by oxidative stress in cardiac myocytes. , 2000, Circulation research.

[26]  N. Bottini,et al.  Negative Feedback Regulation of the Tumor Suppressor PTEN by Phosphoinositide-Induced Serine Phosphorylation1 , 2002, The Journal of Immunology.

[27]  E. Olson,et al.  Activated glycogen synthase-3β suppresses cardiac hypertrophy in vivo , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[28]  José Luis de la Pompa,et al.  Negative Regulation of PKB/Akt-Dependent Cell Survival by the Tumor Suppressor PTEN , 1998, Cell.

[29]  A. Voors,et al.  Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. , 2006, Journal of the American College of Cardiology.

[30]  I. Konstantinov,et al.  Early gene expression profiles during intraoperative myocardial ischemia-reperfusion in cardiac surgery. , 2007, The Journal of thoracic and cardiovascular surgery.

[31]  J. Penninger,et al.  Insulin-like growth factor-1 and PTEN deletion enhance cardiac L-type Ca2+ currents via increased PI3Kalpha/PKB signaling. , 2006, Circulation research.

[32]  P. Hawkins,et al.  The G beta gamma sensitivity of a PI3K is dependent upon a tightly associated adaptor, p101. , 1997, Cell.

[33]  K. Okkenhaug,et al.  The p110β isoform of phosphoinositide 3-kinase signals downstream of G protein-coupled receptors and is functionally redundant with p110γ , 2008, Proceedings of the National Academy of Sciences.

[34]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[35]  I. Batty,et al.  The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif. , 2004, The Biochemical journal.

[36]  D. Catalucci,et al.  Effects of Akt on cardiac myocytes: location counts. , 2006, Circulation research.

[37]  B. Nürnberg,et al.  Phosphoinositide 3-kinase isoforms selectively couple receptors to vascular L-type Ca(2+) channels. , 2001, Circulation research.

[38]  B. Hemmings,et al.  PKB Binding Proteins Getting in on the Akt , 2002, Cell.

[39]  W. Koch,et al.  Gβγ-dependent Phosphoinositide 3-Kinase Activation in Hearts with in Vivo Pressure Overload Hypertrophy* , 2000, The Journal of Biological Chemistry.

[40]  Y. Maejima,et al.  Distinct roles of GSK-3α and GSK-3β phosphorylation in the heart under pressure overload , 2008, Proceedings of the National Academy of Sciences.

[41]  A. Toker,et al.  3'-phosphoinositide-dependent kinase-1 (PDK-1) in PI 3-kinase signaling. , 2002, Frontiers in bioscience : a journal and virtual library.

[42]  P. Backx,et al.  PI3K&ggr; Is Required for PDE4, not PDE3, Activity in Subcellular Microdomains Containing the Sarcoplasmic Reticular Calcium ATPase in Cardiomyocytes , 2007, Circulation research.

[43]  L. Cantley,et al.  Pathways for phosphoinositide synthesis. , 1999, Chemistry and physics of lipids.

[44]  I. Shiojima,et al.  Akt Activity Negatively Regulates Phosphorylation of AMP-activated Protein Kinase in the Heart* , 2003, Journal of Biological Chemistry.

[45]  D. Yellon,et al.  Second window of protection following myocardial preconditioning: an essential role for PI3 kinase and p70S6 kinase. , 2003, Journal of molecular and cellular cardiology.

[46]  M. Crow,et al.  Phosphatidylinositol 3-kinase functionally compartmentalizes the concurrent G(s) signaling during beta2-adrenergic stimulation. , 2002, Circulation research.

[47]  D. Malan,et al.  Phosphoinositide 3-kinase gamma-deficient hearts are protected from the PAF-dependent depression of cardiac contractility. , 2003, Cardiovascular research.

[48]  Anthony J. Muslin,et al.  Akt2 Regulates Cardiac Metabolism and Cardiomyocyte Survival* , 2006, Journal of Biological Chemistry.

[49]  B. Hemmings,et al.  Structure, regulation and function of PKB/AKT--a major therapeutic target. , 2004, Biochimica et biophysica acta.

[50]  M. Birnbaum,et al.  Akt2, phosphatidylinositol 3-kinase, and PTEN are in lipid rafts of intestinal cells: role in absorption and differentiation. , 2004, Gastroenterology.

[51]  J. Downey,et al.  Preconditioning the myocardium: from cellular physiology to clinical cardiology. , 2003, Physiological reviews.

[52]  W. Manning,et al.  Rapamycin Attenuates Load-Induced Cardiac Hypertrophy in Mice , 2003, Circulation.

[53]  H. Just,et al.  Regulation of myocardial contractility and cardiac growth , 1997, Journal of Molecular Medicine.

[54]  M. Crackower,et al.  The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. , 2004, Journal of molecular and cellular cardiology.

[55]  A. Clerk,et al.  Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis , 2008, British journal of pharmacology.

[56]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[57]  J. Padbury,et al.  Temporally controlled overexpression of cardiac-specific PI3Kalpha induces enhanced myocardial contractility--a new transgenic model. , 2008, American journal of physiology. Heart and circulatory physiology.

[58]  B. Pieske,et al.  Insulin-Like Growth Factor-1 Exerts Ca2+-Dependent Positive Inotropic Effects in Failing Human Myocardium , 2003, Circulation research.

[59]  H. Wu,et al.  PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Khokha,et al.  Myocardial extra-cellular matrix and its regulation by metalloproteinases and their inhibitors , 2005, Thrombosis and Haemostasis.

[61]  Yunyu Zhang,et al.  Protective effects of exercise and phosphoinositide 3-kinase(p110α) signaling in dilated and hypertrophic cardiomyopathy , 2007, Proceedings of the National Academy of Sciences.

[62]  T. Mak,et al.  Physiological functions of Pten in mouse tissues. , 2003, Cell structure and function.

[63]  C. Downes,et al.  PTEN: The down side of PI 3-kinase signalling. , 2002, Cellular signalling.

[64]  Q. Liang,et al.  Reengineering Inducible Cardiac-Specific Transgenesis With an Attenuated Myosin Heavy Chain Promoter , 2003, Circulation research.

[65]  D. Lambright,et al.  Membrane Recognition and Targeting by Lipid-Binding Domains , 2003, Science's STKE.

[66]  Y. Taniyama,et al.  Elevated myocardial Akt signaling ameliorates doxorubicin-induced congestive heart failure and promotes heart growth. , 2002, Journal of molecular and cellular cardiology.

[67]  E. Lakatta,et al.  The beta(2)-adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through G(i)-dependent coupling to phosphatidylinositol 3'-kinase. , 2000, Circulation research.

[68]  J. Schlessinger,et al.  Signaling by Receptor Tyrosine Kinases , 1993 .

[69]  G. Semenza,et al.  PTEN Activity Is Modulated During Ischemia and Reperfusion: Involvement in the Induction and Decay of Preconditioning , 2005, Circulation research.

[70]  Tobias Schmelzle,et al.  TOR, a Central Controller of Cell Growth , 2000, Cell.

[71]  K. Webster,et al.  Reperfusion-Activated Akt Kinase Prevents Apoptosis in Transgenic Mouse Hearts Overexpressing Insulin-Like Growth Factor-1 , 2001, Circulation research.

[72]  D. Stokoe,et al.  Protein kinase B phosphorylates AHNAK and regulates its subcellular localization , 2001, The Journal of cell biology.

[73]  U. Eriksson,et al.  Phosphoinositide 3-Kinase &ggr;–Deficient Mice Are Protected From Isoproterenol-Induced Heart Failure , 2003 .

[74]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.

[75]  E. Chavakis,et al.  Phosphatidylinositol-3-Kinase-Is Integral to Homing Functions of Progenitor Cells , 2008 .

[76]  M. Waterfield,et al.  Synthesis and function of 3-phosphorylated inositol lipids. , 2001, Annual review of biochemistry.

[77]  Jian Yang,et al.  Alterations in Conserved Kir Channel-PIP2 Interactions Underlie Channelopathies , 2002, Neuron.

[78]  T. Harris,et al.  TOR Signaling , 2003, Science's STKE.

[79]  E. Kranias,et al.  Calcium: Phospholamban: a crucial regulator of cardiac contractility , 2003, Nature Reviews Molecular Cell Biology.

[80]  S. Cook,et al.  Phenotypic Spectrum Caused by Transgenic Overexpression of Activated Akt in the Heart* , 2002, The Journal of Biological Chemistry.

[81]  A. Curcio,et al.  Competitive displacement of phosphoinositide 3-kinase from beta-adrenergic receptor kinase-1 improves postinfarction adverse myocardial remodeling. , 2006, American journal of physiology. Heart and circulatory physiology.

[82]  B. Doble,et al.  GSK-3: tricks of the trade for a multi-tasking kinase , 2003, Journal of Cell Science.

[83]  Stefano Fumagalli,et al.  Disruption of the p70s6k/p85s6k gene reveals a small mouse phenotype and a new functional S6 kinase , 1998, The EMBO journal.

[84]  T. S. P. S.,et al.  GROWTH , 1924, Nature.

[85]  Kenneth M. Yamada,et al.  Phosphatases in cell–matrix adhesion and migration , 2003, Nature Reviews Molecular Cell Biology.

[86]  A. Kessler,et al.  Diversification of cardiac insulin signaling involves the p85 alpha/beta subunits of phosphatidylinositol 3-kinase. , 2001, American journal of physiology. Endocrinology and metabolism.

[87]  E. Murphy,et al.  Phosphorylation of Glycogen Synthase Kinase-3&bgr; During Preconditioning Through a Phosphatidylinositol-3-Kinase–Dependent Pathway Is Cardioprotective , 2002, Circulation research.

[88]  I. Shiojima,et al.  Regulation of cardiac growth and coronary angiogenesis by the Akt/PKB signaling pathway. , 2006, Genes & development.

[89]  M. Mocanu,et al.  Ischemia-reperfusion injury and cardioprotection: investigating PTEN, the phosphatase that negatively regulates PI3K, using a congenital model of PTEN haploinsufficiency , 2008, Basic Research in Cardiology.

[90]  J. Robbins,et al.  The Tumor Suppressor Gene PTEN Can Regulate Cardiac Hypertrophy and Survival* , 2001, The Journal of Biological Chemistry.

[91]  G. Oudit,et al.  Role of PI3 kinase gamma in excitation-contraction coupling and heart disease. , 2007, Cardiovascular & hematological disorders drug targets.

[92]  A. Hsu,et al.  Opioid-Induced Cardioprotection Occurs via Glycogen Synthase Kinase β Inhibition During Reperfusion in Intact Rat Hearts , 2004, Circulation research.

[93]  S. Cook,et al.  Transcriptional Effects of Chronic Akt Activation in the Heart* , 2002, The Journal of Biological Chemistry.

[94]  E. Lakatta,et al.  The β2-Adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-Dependent coupling to phosphatidylinositol 3'-kinase , 2000 .

[95]  P. Kang,et al.  The conserved phosphoinositide 3‐kinase pathway determines heart size in mice , 2000, The EMBO journal.

[96]  K. Wu,et al.  Up-regulation of Endothelial Nitric-oxide Synthase Promoter by the Phosphatidylinositol 3-Kinase γ/Janus Kinase 2/MEK-1-dependent Pathway* , 2001, The Journal of Biological Chemistry.

[97]  G. Schultz,et al.  Roles of Gβγ in membrane recruitment and activation of p110γ/p101 phosphoinositide 3-kinase γ , 2003, The Journal of cell biology.

[98]  Marketa Zvelebil,et al.  Phosphoinositide 3-kinase signalling--which way to target? , 2003, Trends in pharmacological sciences.

[99]  P. Hawkins,et al.  Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: a new intracellular signalling system? , 1993, Biochimica et biophysica acta.

[100]  J. Ross,et al.  Akt induces enhanced myocardial contractility and cell size in vivo in transgenic mice , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[101]  P. Tsichlis,et al.  AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. , 1999, Annual review of biochemistry.

[102]  G. Ragsdell.  Systems , 2002, Economics of Visual Art.

[103]  Mark A Sussman,et al.  Cardiac Stem Cell and Myocyte Aging, Heart Failure, and Insulin-Like Growth Factor-1 Overexpression , 2004, Circulation research.

[104]  G. Baillie,et al.  cAMP-Specific phosphodiesterase-4 enzymes in the cardiovascular system: a molecular toolbox for generating compartmentalized cAMP signaling. , 2007, Circulation research.

[105]  L. Blatter,et al.  Signaling Mechanisms That Mediate Nitric Oxide Production Induced by Acetylcholine Exposure and Withdrawal in Cat Atrial Myocytes , 2003, Circulation research.

[106]  Holger Gerhardt,et al.  Angiogenesis selectively requires the p110α isoform of PI3K to control endothelial cell migration , 2008, Nature.

[107]  M. Crackower,et al.  Loss of PTEN attenuates the development of pathological hypertrophy and heart failure in response to biomechanical stress. , 2008, Cardiovascular research.

[108]  C. Kahn,et al.  Regulation of Myocardial Contractility and Cell Size by Distinct PI3K-PTEN Signaling Pathways , 2002, Cell.

[109]  P. Hawkins,et al.  The Gβγ Sensitivity of a PI3K Is Dependent upon a Tightly Associated Adaptor, p101 , 1997, Cell.

[110]  M. J. Fry,et al.  The phosphoinositide (PI) 3-kinase family , 2003, Journal of Cell Science.

[111]  P. Kang,et al.  Akt/Protein Kinase B Promotes Organ Growth in Transgenic Mice , 2002, Molecular and Cellular Biology.

[112]  Hui-zhen Wang,et al.  Normal function of HERG K+ channels expressed in HEK293 cells requires basal protein kinase B activity , 2003, FEBS letters.

[113]  B. Nürnberg,et al.  Analysis of class I phosphoinositide 3-kinase autophosphorylation sites by mass spectrometry. , 2003, Rapid communications in mass spectrometry : RCM.

[114]  P. Kang,et al.  Phosphoinositide 3-kinase(p110α) plays a critical role for the induction of physiological, but not pathological, cardiac hypertrophy , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[115]  D. Alessi,et al.  Deficiency of PDK1 in cardiac muscle results in heart failure and increased sensitivity to hypoxia , 2003, The EMBO journal.

[116]  C. Eng,et al.  The nuclear affairs of PTEN , 2008, Journal of Cell Science.

[117]  U. Eriksson,et al.  Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure. , 2003, Circulation.

[118]  Tony Pawson,et al.  Specificity in Signal Transduction From Phosphotyrosine-SH2 Domain Interactions to Complex Cellular Systems , 2004, Cell.

[119]  C. Croce,et al.  Mechanism of Enhanced Cardiac Function in Mice with Hypertrophy Induced by Overexpressed Akt* , 2003, Journal of Biological Chemistry.

[120]  M. Mocanu,et al.  PI3 kinase and not p42/p44 appears to be implicated in the protection conferred by ischemic preconditioning. , 2002, Journal of molecular and cellular cardiology.

[121]  Wonhwa Cho,et al.  Membrane-binding and activation mechanism of PTEN , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[122]  E. Olson,et al.  Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[123]  P. Sugden.  Ras, Akt, and Mechanotransduction in the Cardiac Myocyte , 2003, Circulation research.

[124]  J. Ingwall,et al.  Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts , 2003, Nature Medicine.

[125]  A. Kessler,et al.  Molecular mechanisms of contraction-regulated cardiac glucose transport. , 2000, The Biochemical journal.

[126]  J. Behlke,et al.  The carboxyl‐terminal region of ahnak provides a link between cardiac L‐type Ca2+ channels and the actinbased cytoskeleton , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[127]  J. Penninger,et al.  Insulin-Like Growth Factor-1 and PTEN Deletion Enhance Cardiac L-Type Ca2+ Currents via Increased PI3Kα/PKB Signaling , 2006 .

[128]  G. Breithardt,et al.  Dynamic regulation of MEK/Erks and Akt/GSK-3beta in human end-stage heart failure after left ventricular mechanical support: myocardial mechanotransduction-sensitivity as a possible molecular mechanism. , 2003, Cardiovascular research.